News

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

6641 3734 Samuel Krebs

Natalizumab 300 mg every 4 weeks (Q4W) is approved for the treatment of relapsing-remitting multiple sclerosis (MS). In patients previously exposed to the JC virus, natalizumab is associated with a…

read more

To stay or to switch? Assessing long-term treatment outcomes and impact of treatment on patients’ quality of life

6641 3734 Samuel Krebs

The main concerns of patients, regarding their treatment, include disease control and safety, but they also want to make sure that their day-to-day life remains as close to normal as…

read more

Getting the complete clinical picture: A closer look at smouldering MS

6641 3734 Samuel Krebs

Multiple sclerosis (MS) is an inflammatory disease that is often dominated by relapsing-remitting symptoms.1 However, inflammation is not only present in acute and relapsing MS, but also in the secondary…

read more

Integrative medicine for multiple sclerosis: Outcomes from the Inspire MS program

5692 3201 Samuel Krebs

A growing body of evidence suggests that integrative medicine (IM) modalities can enhance the comprehensive care of patients with multiple sclerosis (MS). Thirty to eighty percent of patients with MS…

read more

Speaking to Prof. Barbara Tettenborn – “You have to love what you do, otherwise you are not good”

1500 1001 Anna Stelling, PhD

Prof. Barbara Tettenborn is the chief of the Department of Neurology at the Cantonal Hospital St. Gallen, Switzerland since 1999. In addition to her position at the hospital, she is…

read more

New guidelines for the use of MRI in patients with multiple sclerosis

1000 665 Anna Stelling, PhD

Magnetic resonance imaging (MRI) in patients with multiple sclerosis (MS) is a well-established tool for diagnostic, prognostic and disease monitoring purposes.1 Its use has been specified in various guideline papers…

read more

The female stroke: Sex differences affect stroke presentation and management

1000 562 Bradley Schussel

Women have a unique experience when it comes to stroke. Several differences between the sexes exist in stroke; in the epidemiology of the disease, clinical presentation, medical care and patient…

read more

Dopamine in stroke rehabilitation – Where do we stand?

1000 562 Anna Stelling, PhD

During this year’s “Stroke Summer School 2021” in Basel, Switzerland, Stefan Engelter (Stroke Unit, University Hospital Basel, Switzerland) provided an overview of what is known about the use of dopamine…

read more

Lipids and stroke: An update

950 535 Anna Stelling, PhD

During this year’s “Stroke Summer School 2021” in Basel, Switzerland, Gian Marco De Marchis (Stroke Unit, University Hospital Basel, Switzerland) provided an overview of the most important recent findings regarding…

read more

Journal watch: Can seizure risk in focal epilepsy be forecasted?

1500 1000 Anna Stelling, PhD

The Background The unpredictability of spontaneous seizures is a major burden for epilepsy patients, affecting their independence, safety and psychological wellbeing. In recent years, several studies utilised continuous electroencephalogram (cEEG)…

read more
Brainwork is supported by unrestricted grants from: